Claims for Patent: 12,458,591

Summary for Patent: 12,458,591

Title:	Intranasal pharmaceutical dosage forms comprising naloxone
Abstract:	The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤250 μl. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
Inventor(s):	John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
Assignee:	Harm Reduction Therapeutics Inc
Application Number:	US18/370,116
Patent Claims:	1. A method of treating opioid overdosing or at least one symptom thereof, the method comprising intranasally administering to a patient in need thereof 100 μl of an intranasal pharmaceutical dosage form comprising naloxone or a pharmaceutically acceptable salt thereof dissolved in an application fluid in a final concentration equivalent to between 13 mg naloxone HCl per ml application fluid and 66 mg naloxone HCl per ml application fluid. 2. The method of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to between 20 mg naloxone HCl per ml application fluid and 60 mg naloxone HCl per ml application fluid. 3. The method of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to between 20 mg naloxone HCl per ml application fluid and 50 mg naloxone HCl per ml application fluid. 4. The method of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to between 18 mg naloxone HCl per ml application fluid and 20 mg naloxone HCl per ml application fluid. 5. The method of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to between 13 mg naloxone HCl per ml application fluid and 16 mg naloxone HCl per ml application fluid. 6. The method of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to 66 mg naloxone HCl per ml application fluid. 7. The method of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to 40 mg naloxone HCl per ml application fluid. 8. The method of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to 20 mg naloxone HCl per ml application fluid. 9. The method of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to 15 mg naloxone HCl per ml application fluid. 10. The method of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to 13 mg naloxone HCl per ml application fluid. 11. The method of claim 1, wherein the application fluid is water or an aqueous saline solution. 12. The method of claim 1, wherein the dosage form is provided in a single dosing unit or two dosing units, dependent on whether the dosage form is provided by administration to one nostril or by administration to two nostrils. 13. The method of claim 1, wherein the dosage form is a nasal spray, a nasal mucoadhesive dosage form, or a mucosal atomizer device. 14. The method of claim 1, wherein the naloxone or pharmaceutically acceptable salt thereof is the only pharmaceutically active compound in the dosage form. 15. The method of claim 1, wherein the dosage form is co-administered with an intramuscular and/or intravenous dosage form comprising naloxone or a pharmaceutically acceptable salt thereof. 16. The method of claim 13, wherein the dosage form is provided in a single dosing unit for administration to one nostril. 17. The method of claim 13, wherein the dosage form is provided in two dosing units for administration to two nostrils, and wherein each dosing unit comprises half of the naloxone or pharmaceutically acceptable salt thereof in the dosage form.